Skip to main content

JAK Inhibitor Deal Benchmarks in Immunology & Autoimmune

Median Upfront
$513M
Range: $272M - $743M
Total Deal Value
$2.7B
Range: $1.7B - $3.7B
Royalty Rate
13.5% - 22.5%
Tiered up to 26.5%
Dev Milestones
$432M
Range: $277M - $590M
Model Your Deal

Market Analysis

JAK Inhibitor therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 jak inhibitor asset in immunology & autoimmune is $513M, with total deal values reaching $2.7B. Development milestones average $432M, while regulatory milestones contribute $757M.

The immunology & autoimmune jak inhibitor landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for jak inhibitor immunology & autoimmune deals range from 13.5% to 22.5% at the base tier, with tiered escalation reaching 17.5%-26.5% on blockbuster sales. Commercial milestones averaging $973M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a jak inhibitor immunology & autoimmune licensing deal?
Based on our analysis, Phase 2 jak inhibitor licensing deals in immunology & autoimmune average $513M in upfront payments, with a range of $272M to $743M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for jak inhibitor immunology & autoimmune transactions?
The median total deal value for Phase 2 jak inhibitor assets in immunology & autoimmune is $2.7B, ranging from $1.7B to $3.7B. This includes development milestones ($432M), regulatory milestones ($757M), and commercial milestones ($973M).
What royalty rates are standard for jak inhibitor deals in immunology & autoimmune?
Base royalty rates for jak inhibitor immunology & autoimmune transactions range from 13.5% to 22.5%, with tiered escalations reaching 17.5%-26.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in jak inhibitor immunology & autoimmune deals?
JAK Inhibitor immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($432M) make up the largest share, followed by commercial milestones ($973M) and regulatory milestones ($757M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

JAK Inhibitor in Dermatology

View

JAK Inhibitor in Gastroenterology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included